[1]
S. K. M, J. D. Katamreddy, and J. R. P, “A review on ANDA submission requirements for Generic drugs: ‘Paragraph IV certification’ as per FDA CDER guidelines”, Int J Drug Reg Affairs, vol. 6, no. 3, pp. 5-12, Sep. 2018.